ROSGQ — Rosetta Genomics Share Price
Last trade - 00:00- $0.00m
- -$1.23m
- $9.23m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | 0 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -366.39% | ||
| Return on Equity | -170.31% | ||
| Operating Margin | -219.63% | ||
Financial Summary
| Year End 31st Dec | Unit | 2012 | 2013 | 2014 | 2015 | 2016 | 2017E | 2018E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.2 | 0.41 | 1.33 | 8.27 | 9.23 | n/a | n/a | 145.76% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Rosetta Genomics Ltd. is an Israel-based company engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA), and protein biomarkers, and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). The Company is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY, and RosettaGX Reveal. The Company's therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. The Company focuses on developing a diagnostic assay, RosettaGX Reveal V2. It is also focusing on developing Bladder cancer risk stratification.
Directors
- Brian Markison NEC (56)
- Ron Kalfus CFO (41)
- Sigal Russo-Gueta FID (38)
- Dganit Bar CSO (47)
- Eti Meiri VPR (47)
- Roy Davis DRC (69)
- Gerald Dogon IND (76)
- Joshua Rosensweig IND (63)
- David Sidransky IND (55)
- Tali Yaron-Eldar IND (52)
- Last Annual
- December 31st, 2016
- Last Interim
- June 30th, 2017
- Incorporated
- March 9th, 2000
- Public Since
- February 27th, 2007
- No. of Employees
- 86
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 5,929,860
- Address
- 10 Plaut Street, Science Park, Pob 4059, REHOVOT, 76706
- Web
- https://rosettagenomics.com/
- Phone
- +972 732220700
- Auditors
- Kost, Forer, Gabbay & Kasierer
Upcoming Events for ROSGQ
Similar to ROSGQ
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
As of Today at 22:59 UTC, shares in Rosetta Genomics are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Rosetta Genomics last closed at $0.00 and the price had moved by -99% over the past 365 days. In terms of relative price strength the Rosetta Genomics share price has underperformed the S&P500 Index by -99.07% over the past year.
There is no consensus recommendation for this security.
Find out moreRosetta Genomics does not currently pay a dividend.
Rosetta Genomics does not currently pay a dividend.
Rosetta Genomics does not currently pay a dividend.
To buy shares in Rosetta Genomics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Rosetta Genomics had a market capitalisation of $0.00m.
Here are the trading details for Rosetta Genomics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ROSGQ
Based on an overall assessment of its quality, value and momentum Rosetta Genomics is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rosetta Genomics. Over the past six months, its share price has outperformed the S&P500 Index by +3.51%.
As of the last closing price of $0.00, shares in Rosetta Genomics were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Rosetta Genomics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Rosetta Genomics' management team is headed by:
- Brian Markison - NEC
- Ron Kalfus - CFO
- Sigal Russo-Gueta - FID
- Dganit Bar - CSO
- Eti Meiri - VPR
- Roy Davis - DRC
- Gerald Dogon - IND
- Joshua Rosensweig - IND
- David Sidransky - IND
- Tali Yaron-Eldar - IND